by Barry101 | Jan 11, 2018 | Press Release
New Technology Simplifies, Speeds Production of Immuno-Oncology CandidateORLANDO, Fla., Jan. 11, 2018 — Hemispherx Biopharma, Inc. (NYSE American:HEB), has successfully tested a new chemical catalyst used in the manufacturing process of Ampligen®, a novel...
by Barry101 | Jan 9, 2018 | Press Release
Ampligen from Hemispherx Shows Potential to Make Tumors More Responsive to Checkpoint InhibitorsORLANDO, Jan. 09, 2018 — Hemispherx Biopharma, Inc. (NYSE American:HEB), focused on pharmaceutical research, today announced that Pawel Kalinski, MD, PhD, Rustum...
by Barry101 | Jan 2, 2018 | Press Release
ORLANDO, Fla., Jan. 02, 2018 — Hemispherx Biopharma, Inc. (NYSE American:HEB), based in Orlando, FL, focused on pharmaceuticals, today announced that Thomas K. Equels, M.S. J.D., Chief Executive Officer, was interviewed on CEOLIVE.TV on January 2nd, 2018.The...
by Barry101 | Dec 29, 2017 | Press Release
ORLANDO, Fla., Dec. 29, 2017 — Hemispherx Biopharma, Inc. (NYSE MKT:HEB), focused on pharmaceutical research, today announced, that it will be presenting at the Biotech Showcase™ 2018. The conference will be held January 8-10, 2018 at the Hilton San...
by Barry101 | Dec 20, 2017 | Press Release
NEW BRUNSWICK, N.J., Dec. 20, 2017 — Hemispherx Biopharma (NYSE American:HEB) said, its Contract Manufacturing Organization (CMO) for Ampligen® has completed a commercial scale demonstration/engineering manufacturing run, along with the...
by Barry101 | Dec 19, 2017 | Press Release
Letter to Shareholders Posted on WebsiteRevenue Up, Burn Rate Down Dramatically; Progress Cited with FDA Discussions on Ampligen; Manufacturing Facility for FDA-Approved Alferon N Fully Repaired; Immuno-oncology Seen as Major OpportunityPHILADELPHIA, Dec. 19, 2017...
